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Abstract
Introduction: Internal jugular vein thrombosis (IJVT) is a rare but potentially fatal condition. It
usually arises following trauma to the internal jugular vein but is also seen in association with
coagulopathies and advanced malignancies as part of a para-neoplastic syndrome.
Case presentation: We report a case of a 44 year old woman with a strong past medical history
and family history of thrombotic disease who presented with abdominal pain and ascites. A stage
III ovarian carcinoma was diagnosed and she underwent debulking of the tumour. She sustained a
peri-operative haemorrhage and required insertion of a central line into the right internal jugular
vein. At one month follow-up she presented as an emergency with a left neck mass and painful
swallowing. A duplex ultrasound of her neck identified a left IJVT to the level of the brachiocephalic
vein which had occurred despite warfarinisation and an INR of greater than 2. She was commenced
on intravenous heparin and the swelling resolved over the course of a week.
Conclusion: This case illustrates an unusual presentation of a rare condition. In this case, the
precise aetiology is unclear as the IJVT may have been related to a coagulopathy or the presence
of advanced malignancy and occurred despite adequate anticoagulation.
Introduction
Internal jugular vein thrombosis (IJVT) was first described
in 1912 by Long as a complication of a peritonsillar
abscess [1]. It is an uncommon condition, but can be fatal.
The two leading causes of IJVT are iatrogenic trauma sec-
ondary to jugular vein catheterisation, and repeated injec-
tions into the vein by intravenous drug users [2]. Other
recognised causes include malignancy, ovarian hyperstim-
ulation syndrome and coagulation disorders. The most
serious complication from an IJVT is pulmonary embo-
lism (PE). The aims of anticoagulation therapy, the treat-
ment of IJVT, is to inhibit further thrombus formation
and prevent embolisation.
Case presentation
A 44 year old woman was admitted as an emergency on
the surgical intake with right upper quadrant pain and
vomiting. Her abdomen was distended and non-tender.
She had a past history of a left-sided ileofemoral deep
venous thrombosis (DVT) complicated by a PE, and a
recurrent left-sided DVT following a long-haul flight. She
had a positive family history of DVTs. The patient was
known to be heterozygous for Factor V Leiden and Pro-
thrombin 20210A variant. She was taking long-term war-
farin, with an international normalised ratio (INR)
maintained between 2.0 and 2.5.
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ascitic tap contained malignant cells. Following resuscita-
tion and investigation she was taken for laparotomy at
which the pelvis was found to be 'frozen' with malig-
nancy. There were secondary deposits throughout the per-
itoneum, omentum and liver. Biopsy of the left ovary
provided a diagnosis of Stage III ovarian carcinoma. After
debulking the tumour, the patient bled peri-operatively
and was resuscitated on the intensive care unit, where a
right-sided central jugular line and a left-sided peripheral
line were placed. No lines were attempted or placed in the
left neck. Her postoperative recovery was otherwise unre-
markable and she was discharged after one week.
One month later the patient was readmitted with a two-
day history of left-sided neck swelling and painful swal-
lowing. Her INR on admission was 2.0. A duplex ultra-
sound of her neck identified a left IJVT to the level of the
brachiocephalic vein (Figure 1). The patient was placed
on intravenous heparin until her INR had stabilised at 3.0,
when she was discharged. The swelling resolved over the
course of a week and she had no recurrence of her symp-
toms.
Discussion
Internal jugular vein thrombosis is an uncommon but
potentially fatal condition. The most serious complica-
tions are septic emboli, septicaemia and pulmonary
embolism, the latter having an incidence of 5% [1].
Cohen and colleagues recommend treating patients with
one week of intravenous heparin and a three month
course of oral warfarin therapy, together with a one week
course of intravenous antibiotic prophylaxis.
In this case, the left IJVT thosmbosis would appear to have
spontaneous. However, it si conceivable, that in addition
to the recognised haematological risk factors, the inser-
tion of a right-sided line at the time of cytoreduction sur-
gery may have inadvertently traumatised the left
brachiocephalic thus further adding to the risk of the sub-
sequent left sided jugular thrombosis.
Carrington et al. [3] reported two cases of IJVT in patients
with advanced malignancy, one from an ovarian cancer
and the second a mesothelioma. Both were treated with
heparin and warfarin. Metastatic adenocarcinoma induces
a migratory thrombophlebitis secondary to the hyperco-
agulable state of cancer. This is seen in 5% of patients with
cancer and more than 90% of patients with metastases
will have some form of coagulation disorder [2].
Arullendran et al. [4] reported a case of a left IJVT in a
patient with Factor V Leiden mutation. The importance of
inactivated Factor V in haemostasis is that it inhibits clot
formation. In a patient with the mutation, Factor V is
resistant to inactivation, therefore coagulation is not
inhibited and indeed there is a high risk of spontaneous
thrombosis – a patient with a homozygous mutation has
an eighty-fold increased risk of venous thrombosis. The
presence of the prothrombin 20210A mutation also sig-
nificantly increases the risk of venous thrombosis, and is
the second most important risk factor for a DVT in the
Caucasian population [5]. The recommended treatment
of both conditions is long-term anticoagulation.
Conclusion
This case has illustrated an unusual presentation of a rare
condition and it remains uncertain as to the precise aeti-
ology of the thrombosis. We would suggest that patients
with IJVT should be formally anticoagulated with intrave-
nous heparin and then be placed on oral anticoagulant
therapy. For high risk patients such as those with factor V
Leiden deficiency or the prothrombin 20210A mutation
presenting with an IJVT, the INR should be maintained at
a higher level, between 2.5 and 3.0, and consideration
should be given to long-term warfarin therapy.
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